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TRAIL is a member of the tumor necrosis factor superfamily
which induces apoptosis in cancer but not in normal cells. Akt1
promotes cell survival and blocks apoptosis. The scope of this
paper was to investigate whether a HL60 human leukemia cell
clone (named AR) with constitutively active Akt1 was resistant
to TRAIL. We found that parental (PT) HL60 cells were very
sensitive to a 6 h incubation in the presence of TRAIL and died
by apoptosis. In contrast, AR cells were resistant to TRAIL con-
centrations as high as 2 g/ml for 24 h. Two pharmacological
inhibitors of PI3K, Ly294002 and wortmannin, restored TRAIL
sensitivity of AR cells. AR cells stably overexpressing PTEN
had lower Akt1 activity and were sensitive to TRAIL. Con-
versely, PT cells stably overexpressing a constitutive active
form of Akt1 became TRAIL resistant. TRAIL activated caspase-
8 but not caspase-9 or -10 in HL60 cells. We did not observe a
protective effect of Bcl-XL or Bcl-2 against the cytotoxic activity
of TRAIL, even though TRAIL induced cleavage of BID. There
was a close correlation between TRAIL sensitivity and intranu-
clear presence of the p50 subunit of NF-B. Higher levels of
the FLICE inhibitory protein, cFLIPL, were observed in TRAIL-
resistant cells. Both the cell permeable NF-B inhibitor SN50
and cycloheximide lowered cFLIPL expression and restored
sentivity of AR cells to TRAIL. Our results suggest that Akt1
may be an important regulator of TRAIL sensitivity in HL60 cells
through the activation of NF-B and up-regulation of cFLIPL
synthesis
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Introduction
Tumor necrosis factor (TNF)-related apoptosis-inducing ligand
(TRAIL) is one of the latest members of the TNF superfamily
known to induce apoptosis in a wide variety of cancer cells.1–
4 The messenger RNA for TRAIL and its receptors are nonethe-
less expressed in a wide range of normal tissues5 so that a
TRAIL physiological role has yet to be envisioned, even
though TRAIL shows inhibitory effects on erythroblasts,6 T
lymphocytes,7 and hepatocytes.8 TRAIL induces apoptosis by
binding DR4 (TRAIL-R1) and DR5 (TRAIL-R2/KILLER/TRICK2)
receptors. DR4 and DR5 are type I transmembrane proteins
that transduce the death signal via their 80-amino acid intra-
cellular death domains (DDs), which recruit adaptor proteins.9
TRAIL receptors are ubiquitously expressed in cancer cells.10
Depending on the cell type being investigated, binding of
TRAIL to DR4 and DR5 leads to activation of caspase-8 or -10,
that in turn, activates downstream effector caspases, caspase-3
and -7 with an ensuing irreversible commitment to apoptotic
cell death.11 In some cell types, activation of caspase-8 by
TRAIL may also cleave BID (a Bcl-2 inhibitory protein) whose
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cleavage product triggers mitochondrial depolarization and
subsequent release of cytochrome c from mitochondria and
activation of caspase-9.12 Two additional TRAIL receptors,
TRAIL-R3/TRID/DcR1 and TRAIL-R4/TRUNDD/DcR2, lack
completely (DcR1) or partially (DcR2) a DD and therefore
cannot induce a proapoptotic signal. Thus, they are con-
sidered ‘decoy receptors’, competing with DR4 and DR5 for
TRAIL binding.13,14 Recently, based on in vitro experiments,
some TRAIL-resistant cell lines have been discovered. The rea-
son for TRAIL resistance is unknown, but it is not regulated
exclusively by the expression of DcR1 and DcR2. Instead, it
seems that intracellular inhibitors acting downstream of TRAIL
receptors are responsible for resistance.12 One of the most
effective antiapoptotic survival pathways in mammals is con-
stituted of phosphoinositide 3-kinase (PI3K)/Akt.15 To date,
three different Akt isoforms have been identified: Akt1, -2,
and -3.16,17 Akt (also referred to as PKB, protein kinase B) is a
serine/threonine protein kinase activated in response to many
stimuli including growth factors such as insulin, insulin-like
growth factor-1, epidermal growth factor, or cytokines such
as interleukin-3, interleukin-6, macrophage colony-stimulat-
ing factor.18,19 These agonists stimulate PI3K which synthe-
sizes 3-phosphoinositides such as phosphatidylinositol 3,4,5-
trisphosphate [PtdIns(3,4,5)P3]. PtdIns(3,4,5)P3 activates the
phosphoinositide-dependent protein kinase PDK-1 which is
recruited at the plasma membrane.16,17 PDK-1 phosphorylates
Akt1 on Thr 308. It is commonly thought that PtdIns (3,4,5)P3
causes a conformational change in Akt with an ensuing
increase of the accessibility to the phosphorylation site. How-
ever, for a full activation of Akt1, phosphorylation of Ser 473
is also required. The kinase responsible for this phosphoryl-
ation is yet to be identified, but it might be PDK-1 or PDK-2,
ILK (integrin-linked kinase) or Akt itself.16,17
Evidence suggests that Akt inhibits apoptosis through mul-
tiple mechanisms. These include direct phosphorylation and
inactivation of proapoptotic proteins such as Bad or procas-
pase-9, increased expression of antiapoptotic proteins (cIAP1,
cIAP2, TRAF-1, TRAF-2, cFLIP, Bcl-2, Mcl-1, A1/Bfl-1), and
down-regulation of proapoptotic proteins such as FAS-L,
IGFBP1, Bim.16,17 Very recently, some articles have demon-
strated that, in cell lines derived from prostatic cancers, Akt1
protects from apoptosis induced by TRAIL (eg Refs 12, 20
and 21).
The purpose of this study was to investigate the intracellular
mechanisms by which an apoptosis-resistant (named AR) cell
clone of HL60 human leukemia cells is insensitive to TRAIL.
We found that these cells have a constitutively active Akt1.
While in TRAIL-sensitive parental (PT) HL60 cells, TRAIL acti-
vates caspase-8, in HL60AR cells this activation did not occur.
Treatment of HL60AR cells with two pharmacological inhibi-
tors of PI3K, wortmannin and Ly294002, restored sensitivity
to TRAIL. If HL60AR cells were transfected with the cDNA
coding for PTEN, they reacquired TRAIL sensitivity. Con-
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versely, forced overexpression of a constitutively active Akt1
rendered HL60PT cells resistant to TRAIL. Expression of the
long variant of the caspase-8 homologue FLICE inhibitory pro-
tein (cFLIPL, a potent negative regulator of death receptor-
induced apoptosis) was up-regulated in HL60AR as compared
to PT cells. Both the cell-permeable NF-B inhibitor, SN50,
and cycloheximide reversed TRAIL resistance in HL60AR cells
and down-regulated the levels of cFLIPL. These data suggest
that elevated Akt1 activity protects HL60AR cells from TRAIL-




G418, etoposide, bovine serum albumin (BSA), normal goat
serum (NGS), normal goat IgG, protein A-Agarose, peroxi-
dase-conjugated and fluorescein isothiocyanate (FITC)-conju-
gated secondary antibodies were from Sigma (St. Louis, MO,
USA). Histone H2B, the COMPLETE Protease Inhibitor Cock-
tail, and the Lumi-LightPlus enhanced chemiluminescence
(ECL) detection kit were from Roche Applied Science (Milan,
Italy). Constitutively active Akt1 murine cDNA (myc-tagged,
cloned in pUSEamp) and PTEN assay kit were from Upstate
Biotechnology (Lake Placid, NY, USA). Phosphatidylinositol
(4,5) bisphosphate [PtdIns(4,5)P2], Ly 294002, wortmannin,
the caspase-8 (Z-IETD-FMK) and caspase-9 (Z-LEHD-FMK)
cell-permeable inhibitors, cycloheximide (CHX) and human
recombinant TRAIL were from Calbiochem (La Jolla, CA,
USA). PtdIns(3,4,5)P3 was from Alexis Biochemical
(Laufelfingen, Switzerland). The SN50 peptide was from
Biomol Research Laboratories (Plymouth Meeting, PA, USA).
The cDNA encoding full-length human PTEN (cloned in
pcDNA3) was a kind gift from Dr S Marmiroli (Istituto di Cito-
morfologia Normale e Patologica del CNR, Bologna, Italy).
The ApoAlert Caspase-8 colorimetric assay kit was from BD
Biosciences Clontech (Palo Alto, CA, USA). The Intraprep kit
for cytoplasmic staining was purchased from Coulter Immu-
nology (Hialeah, FL, USA). The Protein Assay kit (detergent
compatible) was from Bio-Rad (Hercules, CA, USA). cAMP-
dependent protein kinase inhibitor peptide was from Bachem
(Bubendorf, Switzerland). P-81 paper was from Whatman
(Maidstone, UK).
Source of antibodies
The following primary antibodies were used in this study: from
Upstate Biotechnology: rabbit polyclonals to Akt1, cyto-
chrome c, mouse monoclonals to human c-myc (clone 9E10)
and caspase-9; from Santa Cruz Biotechnology (Santa Cruz,
CA): mouse monoclonals to NF-B p50 subunit and FLICE-
inhibitory protein (cFLIPS/L); from Cell Signaling Technology
(Beverly, MA, USA): mouse monoclonals to PTEN and BID,
rabbit polyclonals to caspase-10, Thr 308 phosphorylated
Akt1 (p-Akt1), Ser 473 p-Akt1, Bcl-2, Bcl-XL; from Sigma:
mouse monoclonal to -tubulin, rabbit polyclonal to procas-
pase-8; from R&D Systems (Oxon, UK): goat polyclonals to
extracellular domain of human DR4, DR5, DcR1, DcR2; from
Molecular Probes (Leiden, The Netherlands): rabbit polyclonal
to cytochrome oxidase subunit II (COX II).
Cell culture and differentiation
The HL60 cell line (HL60PT, for parental), obtained from the
American Type Culture Collection (CCL 240), was routinely
maintained in RPMI 1640 supplemented with 10% fetal calf
serum at an optimal cell density of 3 to 8 × 105 cells/ml.
Induction and detection of apoptosis
Sixteen hours after medium change, HL60 cells in exponential
growing phase were treated with TRAIL for 6 h or 24 h at
37°C. In some experiments, prior to apoptotic induction, cells
had been pre-incubated for 24 h with wortmannin (0.1 M)
or Ly294002 (5 M). For detection of apoptosis, samples con-
taining 2 to 5 × 105 cells were harvested by centrifugation at
200 g for 10 min, fixed with 70% cold ethanol for 1 h, and
stained with 20 g/ml propidium iodide for 30 min at room
temperature. For quantitative evaluation of apoptosis, the sub-
diploid DNA content was calculated as described by Nicoletti
et al22 using an Epics XL flow cytometer with the appropriate
software (Coulter Immunology).
Flow cytometric detection of TRAIL receptors
For surface staining the antibodies (concentration 50 g/ml)
were incubated at 4°C for 12 h in a final volume of 50 l with
3 × 105 cells. After two washes in PBS cells were incubated
with FITC-conjugated anti-goat IgG. For analysis of intracyto-
plasmic receptors, we employed a saponin-based technique.23
Briefly, cells were fixed with Reagent 1 of the Intraprep kit,
following the manufacturer’s instructions. Then, cells were
permeabilized with saponin-based Reagent 2 and incubated
at 4°C for 12 h with the antibodies (concentration as above).
Samples were then incubated with FITC-conjugated anti-goat
IgG. Negative controls were run with normal goat IgG plus
FITC-conjugated anti-goat IgG. All samples were analyzed by
Epics XL flow cytometer equipped with dedicated software.
In vivo labeling of polyphosphoinositides, lipid
extraction and thin layer chromatography
Cells were incubated with phosphate-free RPMI 1640/0.5%
BSA for 15 min, then exposed to the same medium plus car-
rier-free 32P ortophosphate (1.0 mCi/ml) at 37°C for 8 h. Cells
(2 × 107), washed twice with ice-cold buffer A (137 mM NaCl,
20 mM Tris, pH 7.4, 1 mM MgCl2, 1 mM CaCl2 and 0.1 mM
Na3VO4), were transferred to a tube containing 3 ml of
chloroform/methanol (1:2) plus 1 mg/ml of butylated hydroxy-
toluene and 10 g of a 1:1:1 mixture of phosphatidyl-
inositol/phosphatidylinositol (4) phosphate/PtdIns (4,5)P2.
After addition of 2.1 ml of chloroform and 2.1 ml of 2.5 M
HCl, the lower phase was collected, and the upper phase was
washed twice with 1 ml of chloroform. The three upper
phases were pooled and dried under vacuum. The lipids were
spotted on a silica plate and separated using chloroform/
acetone/methanol/acetic acid/water (80:30:26:24:14). Plates
were autoradiographed and the position of the products was
compared with migration of unlabelled standards PtdIns
(4,5)P2, and PtdIns (3,4,5)P3. Spots of interest were scraped
and counted by liquid scintillation.
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(myristolated) Akt1
Transfection of HL60 cells was performed by electroporation
with a Bio-Rad Gene Pulser apparatus. Twenty g of plasmid
DNA were mixed with 107 cells in 0.5 ml of phosphate-buff-
ered sucrose (272 mM sucrose and 7 mM Na2HPO4, pH 7.4).
Cells were electroporated with a pulse of 250 V for 18–20 ms.
Control cells were mock-transfected in the same conditions
with the empty vector. Following electroporation, cells were
allowed to recover in 20 ml of culture medium for 48 h before
selection with 600 g/ml of G418. G418-resistant transfected
clones were obtained by limited dilution.
Measurement of caspase-8 activity
This was performed using a colorimetric assay according to
the manufacturer’s instructions. Briefly, samples (100 g of
protein) were incubated with the caspase-8 colorimetric sub-
strate (IETD-pNA) at 37°C for 2 h. The optical density of the
reaction mixture was quantified spectrophotometrically at a
wavelength of 405 nm.
Preparations of mitochondria and cytosol
Cell pellets were resuspended with 5 vol ice-cold buffer A (20
mM Hepes-KOH, pH 7.5, 0.1% BSA, 1 mM EDTA, 1 mM
dithiothreitol (DTT), 0.1 mM phenylmethylsulfonyl fluoride,
20 g/ml leupeptin, 10 g/ml of both aprotinin and pepstatin
A) containing 250 mM sucrose. After swelling on ice for 5
min, the cells were homogenized with 20 strokes of a number
22 Kontes Dounce homogenizer with the B pestle (Kontes
Glass, Vineland, NJ, USA) and the homogenates were centri-
fuged at 750 g for 15 min at 4°C. Supernatants were then pel-
leted at 10 000 g for 15 min at 4°C. Resultant pellets contain-
ing mitochondria were resuspended in cold buffer A.
Supernatants were further cleared at 20 000 g for 30 min at
4°C and used as cytosol. For Western blot analysis, equal
amounts of mitochondrial and cytosol were separated by gel
electrophoresis.
Preparations of cell homogenates and Western blot
analysis
Cells were washed twice in PBS containing the COMPLETE
Protease Inhibitor Cocktail supplemented with 1.0 mM
Na3VO4 and 20 nM okadaic acid. Cells were then lysed at
107/ml in boiling electrophoresis sample buffer containing
the protease and phosphatase inhibitor cocktail. Lysates were
briefly sonicated to shear DNA and reduce viscosity, and
boiled for 5 min to solubilize protein. Protein separated on
SDS-polyacrylamide gels was transferred to nitrocellulose
sheets using a semi-dry blotting apparatus. Bands were vis-
ualized by the ECL method. To ensure equal loading, blots
were always first probed with an antibody to -tubulin, then
stripped and re-probed.
Preparation of cell homogenates for
immunoprecipitation
To obtain homogenates, cells were resuspended in 50 mM
Tris-HCl, pH 7.4, 1 mM EDTA, 1 mM EGTA, 150 mM NaCl,
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1% Triton X-100, supplemented with the protease and phos-
phatase inhibitor cocktail and homogenized by 30 passages
through a 25-gauge needle. Cell homogenates (1 ml, contain-
ing 500 g of protein) were pre-cleared by adding 5 g of
normal rabbit IgG and 10 g of 50% Protein A-Agarose, fol-
lowed by incubation for 1 h at 4°C and centrifugation at
12 000 g for 10 min at 4°C. Then, the samples were incubated
for 2 h at 4°C under constant agitation with 5 g of a poly-
clonal antibody to Akt1. Ten g of 50% Protein A-Agarose
was then added and incubation proceeded for 1 h at 4°C
under constant agitation.
Akt1 activity assay
The immunoprecipitates were washed twice in lysis buffer,
once in distilled water and twice in the Akt1 kinase buffer (20
mM Hepes-NaOH, pH 7.4, 10 mM MgCl2, 10 mM MnCl2, 1
mM DTT) as previously reported.24 Assays (100 l) contained
20 mM Hepes-NaOH, pH 7.4, 10 mM MgCl2, 10 mM MnCl2,
1 mM DTT, 1 M cAMP-dependent protein kinase inhibitor
peptide, 5 g histone H2B as exogenous substrate, 2 M ATP,
10 Ci -32P ATP (3000 Ci/mmole). Samples were incubated
for 30 min at 30°C and the reaction was then stopped by spot-
ting 80 l on to P-81 filter papers and immersing in 1% (v/v)
orthophosphoric acid. The papers were washed several times,
rinsed in ethanol, air-dried, and the radioactivity was determ-
ined by scintillation counting. Background values, obtained
by samples in which the anti-Akt1 antibody was replaced by
normal rabbit IgG, were subtracted from all values.
PTEN activity assay
The assay was performed using the manufacturer’s recommen-
dations.
Immunofluorescent staining
Cells in PBS were plated on to 0.1% poly-L-lysine-coated glass
slides and adhesion was allowed to proceed for 30 min at
room temperature. Samples were fixed in methanol for 10 min
at −20°C. After several washes with PBS, nonspecific binding
of antibodies was blocked by a 30 min incubation at 37°C
with PBS, 2% BSA, 5% NGS. Slides were then incubated for
3 h at 37°C with the antibody to NF-B p50 subunit diluted
1:50 in PBS, 2% BSA. Slides were then washed three times in
PBS and reacted with FITC-conjugated anti-rabbit IgG, diluted
1:200 in PBS, 2% BSA, 5% NGS for 1 h at 37°C. Samples were
subsequently washed three times in PBS, stained for DNA with
0.5 g/ml 4-6-diamidino-2-phenylindole (DAPI) in PBS and
mounted in 20 mM Tris-HCl, pH 8.2, 90% glycerol, contain-
ing 2.3% of the antifading agent 1,4-diazobicyclo-[2.2.2]-
octane. Slides were observed and photographed using a Zeiss
Axiophot epifluorescence microscope.
Results
Akt1 activity in HL60 cells and its inhibition by PI3K
inhibitors
During our previous studies on apoptosis,25,26 we selected a
cell population which was resistant to drugs, such as campto-
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thecin and etoposide, that we employed to induce apoptosis
in HL60 cells. A clone was further isolated on soft agar. We
named this clone HL60AR cells (for apoptosis resistant). As
shown in Figure 1a, Western blotting analysis revealed that
the amount of total Akt1 was similar in HL60PT and AR cells.
Treatment of AR cells with two pharmacological inhibitors of
PI3K, Ly294002 and wortmannin, did not lower the amount
of total Akt1.
However, when the blots were probed with antibodies to
either Thr 308 or Ser 473 p-Akt1, it was evident that HL60AR
cells contained more p-Akt1 than HL60PT cells (Figure 1a).
The levels of p-Akt1 forms of AR cells could be markedly
reduced by a 24 h incubation in the presence of either
Ly294002 or wortmannin (Figure 1a). Consistently, the in vitro
kinase activity of Akt1 was higher in HL60AR when compared
to PT cells. The Akt1 activity of HL60AR cells could be mark-
edly inhibited by treatment with Ly294002 or wortmannin
(Figure 1b).
Figure 1 Akt1 activity in HL60PT or AR cells. Western blot analy-
sis for expression of total Akt1 and p-Akt1 forms (a). For inhibition
with Ly294002 (Ly, 5 M) or wortmannin (wort, 0.1 M) cells were
incubated in the presence of the inhibitors for 24 h. 80 g of protein
was blotted to each lane. The blots are representative of at least three
separate experiments. (b) In vitro Akt1 kinase activity. For inhibition
with Ly294002 (Ly) or wortmannin (wort) cells were incubated in the
presence of the inhibitors for 24 h. The results are the mean ± s.d. of
three separate experiments.
TRAIL sensitivity of HL60 cells
As shown in Figure 2, TRAIL induced apoptosis in HL60PT
cells. A 20 ng/ml concentration was capable of causing apop-
totic cell death in 34% of cells after a 6 h incubation. A 500
ng/ml concentration killed 68% of cells. The efficacy of TRAIL
did not rise significantly if higher concentrations (up to 2
g/ml) were employed. In contrast, HL60AR cells were mark-
edly resistant to TRAIL so that a 2 g/ml concentration
resulted in only about 14% of cells being apoptotic. Further-
more, AR cells were resistant to TRAIL even if the incubation
was prolonged to 24 h, thus demonstrating that the apoptotic
process was not simply delayed in these cells (data not
shown).
If AR cells had been pre-treated with Ly294002 or wortman-
nin, they became much more sensitive to TRAIL. For example,
whereas a 1 g/ml TRAIL concentration killed only approxi-
mately 10% of AR cells, this percentage rose to about 50%
after treatment with the inhibitors. Importantly, Ly294002 or
wortmannin alone did not induce apoptosis in HL60AR cells
(Figure 2).
Analysis of TRAIL receptors
In principle, the lower sensitivity to TRAIL displayed by AR
cells could be due to an expression of TRAIL receptors differ-
ent from PT cells. Therefore, we investigated this issue. As
shown in Figure 3a, Western blotting analysis of DR4, DR5
and DcR2 showed that they were all expressed to the same
extent in HL60PT and AR cells. We did not detect DcR1
receptor in our cells. Moreover, flow cytometric analysis
allowed us also to conclude that the DR4 and DR5 receptors
present at the cell surface did not vary between the two kinds
of cells (Figure 3b). DcR2 receptor was detected only in per-
meabilized cells, suggesting it is located in the cytoplasm.
However, in this case there were also no differences between
PT and AR cells (Figure 3b).
Figure 2 Effect of TRAIL on HL60PT or AR cells. Flow cytometric
analysis for apoptosis in HL60 cells treated for 6 h with increasing
concentrations of human recombinant TRAIL. For inhibition with
Ly294002 (Ly) or wortmannin (wort) cells were incubated in the pres-
ence of the inhibitors for 24 h. The results are the mean ± s.d. of three
separate experiments.
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Figure 3 Expression of TRAIL receptors in HL60PT or AR cells. (A)
Western blot analysis. For inhibition with Ly294002 (Ly) or wortman-
nin (wort) cells were incubated in the presence of the inhibitors for
24 h. 80 g of protein was blotted to each lane. Equal protein loading
was ensured by demonstration of uniform -tubulin expression. The
blots are representative of at least three separate experiments. (B) Flow
cytometric analysis. NEG CTR: negative control (cells were incubated
with normal goat IgG followed by FITC-conjugated anti-goat IgG). The
histograms shown are representative of three separate experiments.
Caspase activation by TRAIL
We next analyzed the caspase activation pattern in response
to TRAIL. As shown in Figure 4a, incubation with TRAIL (1
g/ml for 6 h) induced the cleavage of procaspase-8 in PT
cells, but not in AR cells. However, if AR cells had been pre-
treated with Ly294002 or wortmannin, TRAIL-dependent
cleavage of procaspase-8 was detected by Western blot. In
contrast, we never detected cleavage of procaspase-10 or pro-
caspase-9 in HL60 cells, either PT and AR. BID was cleaved
in HL60PT cells treated with TRAIL, whereas it was not in
AR cells plus TRAIL. However, in AR cells pre-treated with
Ly294002 or wortmannin TRAIL exposure resulted in BID
cleavage.
As presented in Figure 4b, an inhibitor of caspase-8 mark-
edly reduced apoptosis in PT cells treated with 500 ng/ml
TRAIL. On the other hand, a caspase-9 inhibitor was ineffec-
tive. In AR cells pre-treated with Ly294002 or wortmannin, a
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Figure 4 Western blot analysis for caspases and BID and modu-
lation of apoptosis by caspase inhibitors in HL60PT or AR cells. (A)
Western blot analysis. Cells were incubated for 6 h with 1 g/ml
TRAIL. For inhibition with Ly294002 (Ly) or wortmannin (wort) cells
were pre-incubated in the presence of the inhibitors for 24 h. Note
that the antibody to caspase-8 we employed in this study only recog-
nizes the procaspase-8 banding at 55/54 kDa. 80 g of protein was
blotted to each lane. Equal protein loading was ensured by demon-
stration of uniform -tubulin expression. The blots are representative
of at least three separate experiments. (B) Flow cytometric analysis
showing the effect of caspase-8 (Z-IETD-FMK) and caspase-9 (Z-
LEHD-FMK) inhibitors on TRAIL-induced apoptosis. Cells were pre-
treated for 1 h with the inhibitors (used at 25 M) before a 6 h incu-
bation with TRAIL. For inhibition with Ly294002 (Ly) or wortmannin
(wort) cells were pre-incubated in the presence of the inhibitors for
24 h. The results are the mean ± s.d. of three separate experiments.
caspase-8 inhibitor markedly reduced TRAIL-dependent
apoptosis. In contrast, in AR cells pre-treated with Ly294002
or wortmannin an inhibitor of caspase-9 was still ineffective
in preventing apoptosis.
Bcl-XL and Bcl-2 expression and cytochrome c release
in HL60PT and AR cells
Since previous results indicated that both Bcl-XL and Bcl-2,
when overexpressed in HL60 cells, could block TRAIL-
induced apoptosis,27,28 we analyzed the expression levels of
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these two antiapoptotic proteins in HL60PT and AR cells. As
shown in Figure 5a, Western blots showed that Bcl-XL was
indeed much more abundant in AR than in PT cells. However,
treatment with PI3K inhibitors, Ly294002 and wortmannin,
which restored TRAIL sensitivity of AR cells, did not lower the
amount of Bcl-XL present in these cells. As far as Bcl-2 was
concerned, its expression was lower in AR than in PT cells
(Figure 5b). As further evidence that TRAIL did not induce
apoptosis through the mitochondrial pathway in HL60 cells,
we analyzed cytochrome c release from mitochondria. As
presented in Figure 5c, we never detected an increase in the
amount of cytosolic cytochrome c in either PT cells treated
with TRAIL or in AR cells pre-treated with Ly294002 followed
by incubation with TRAIL, ie two conditions which resulted
in a large number of HL60 cells undergoing apoptosis. In con-
trast, there was a massive release of cytochrome c from mito-
chondria in etoposide-exposed PT cells (Figure 5c), a treat-
ment which resulted in about 50% of apoptotic cells (not
shown). COX II served as a control to rule out gross mitochon-
drial contamination of the cytosolic extracts.29
Figure 5 Bcl-XL and Bcl-2 expression and cytochrome c release in
HL60PT and AR cells. Western blot analysis for Bcl-XL (a) or Bcl-2
(b). 80 g of protein was blotted to each lane. In (a) equal protein
loading was ensured by demonstration of uniform -tubulin
expression. (C) Western blot analysis for cytochrome c and COX II in
cytosol and mitochondria (MIT). Cell were treated with 500 ng/ml
TRAIL or 5.0 g/ml etoposide for 6 h. For inhibition with Ly294002
(Ly) cells were pre-incubated in the presence of the inhibitors for 24 h.
80 g of protein was blotted to each lane. The blots are representative
of at least three separate experiments.
Overexpression of PTEN restores TRAIL sensitivity in
HL60AR cells
Since the dual phosphatase PTEN, by converting
PtdIns(3,4,5)P3 to PtdIns(4,5)P2, is a regulator of Akt1
activity,30 we sought to examine the effects of human PTEN
overexpression on TRAIL-induced apoptosis in HL60AR cells.
Cells were transfected with either the empty vector or the full-
length construct. As shown in Figure 6a, we selected three
stably transfected clones that, by Western blotting, displayed
enhanced expression of PTEN. In contrast, mock-transfected
cells had PTEN levels comparable to untransfected HL60AR
cells. We next assayed the levels of PtdIns(3,4,5)P3 synthe-
sized in vivo by these clones. As presented in Figure 6b, all
three of the clones had PtdIns(3,4,5)P3 levels markedly lower
than untransfected HL60AR cells. Also, in vitro PTEN activity
was increased in these clones (Figure 6c), whereas in vitro
Akt1 kinase activity was decreased (Figure 6d). Cell clones
overexpressing PTEN, but not mock-transfected cells, were
sensitive to a 6 h treatment with 500 ng/ml TRAIL (Figure 5e).
Overexpression of constitutively active Akt1 renders
HL60PT cells resistant to TRAIL
We next tried to determine whether or not overexpression of a
constitutively active (myristolated) Akt1 could protect HL60PT
cells from TRAIL-induced apoptosis. Also in this case, cells
were transfected with either the empty vector or the full-length
construct. In Figure 7a, we show that we selected three stably
transfected cell clones overexpressing similar amounts of Akt1
protein. To reveal the bands, we used an antibody to the myc
tag. Therefore, when we assayed untransfected and mock-
transfected HL60PT cells, we did not detect any bands corre-
sponding to Akt1. In vitro Akt1 kinase activity was increased
in these clones (Figure 7b). If these clones were exposed for
6 h to 2 g/ml TRAIL, only about 11–14% of cells underwent
apoptotic cell death (Figure 7c).
Analysis of NF-B immunofluorescent intracellular
distribution
To exert its anti-apoptotic effect, Akt1 targets several down-
stream proteins.16,17 We examined NF-B transcription factor.
When inactive, this protein resides as a complex in the cyto-
plasm. Following Akt1 activation, the p50 subunit of NF-B
migrates to the nucleus.17 Therefore, we studied the intracellu-
lar distribution of the p50 NF-B subunit by immunofluoresc-
ence staining. In HL60PT cells, this subunit was localized in
the cytoplasm (Figure 8a, b). In contrast, in AR cells, it was
present within the nucleus (Figure 8c, d). If AR cells were
treated with Ly294002, the p50 NF-B subunit subcellular dis-
tribution resembled that of PT cells (Figure 8e, f). Also if AR
cells had been treated with SN50 (a synthetic peptide which
inhibits intranuclear translocation and transcriptional activity
of NF-B, see Ref. 31) p50 NF-B subunit was mainly distrib-
uted in the cytoplasm (Figure 8g, h). p50 NF-B subunit was
also cytoplasmic in cell clone 4H1 (which overexpresses
PTEN, see Figure 8i, j), whereas it was nuclear in clone 12FC
(which overexpresses constitutively active Akt1, see Figure
8k, l).
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Figure 6 Overexpression of human PTEN sensitizes HL60AR cells
to TRAIL. (A) Western blot analysis for PTEN expression in HL60AR,
mock-transfected HL60AR cells (AR MT) and in three stably trans-
fected clones. 80 g of protein was blotted to each lane. The blot is
representative of at least three separate experiments. (B) Levels of in
vivo synthesized PtdIns (3,4,5)P3 in HL60AR cells and in the three
stably transfected clones overexpressing PTEN. A representative auto-
radiograph from three separate experiments is shown. In this experi-
ment, incorporation was 1987 c.p.m. for AR cells, 604 c.p.m. for
clone 4H1, 559 c.p.m. for clone 4H9 and 517 c.p.m. for clone 7E5.
(C) In vitro PTEN activity in HL60AR, AR MT cells, and in three stably
transfected clones; 100% of the activity was 257.1 ± 21.4 pmoles P
released/reaction. (D) In vitro Akt1 kinase activity in HL60AR, AR MT
cells, and in three stably transfected clones; 100% of the activity was
4087 ± 356 c.p.m. incorporated/reaction. (E) Flow cytometric analysis
for TRAIL-induced apoptosis (500 ng/ml TRAIL for 6 h) in HL60AR,
AR MT cells, and in three stably transfected clones. In c,d, e, the
results are the mean ± s.d. of three separate experiments.
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Figure 7 Overexpression of constitutively active Akt1 renders
HL60PT cells resistant to TRAIL. (A) Western blot analysis for Akt1
expression in HL60PT, mock-transfected HL60PT cells (PT MT), and
in three stably transfected clones. 80 g of protein was blotted to each
lane. Overexpressed Akt1 was revealed by means of a monoclonal
antibody to the myc-tag. The blot is representative of at least three
separate experiments. (B) In vitro Akt1 kinase activity in HL60PT, PT
MT cells, and in three stably transfected clones; 100% of the activity
was 4234 ± 378 c.p.m. incorporated/reaction. (C) Flow cytometric
analysis of TRAIL-induced apoptosis (2 g/ml TRAIL for 6 h) in
HL60PT, PT MT cells, and in three stably transfected clones. In (B)
and (C) the results are the mean ± s.d. of three separate experiments.
cFLIP and TRAIL receptor expression in relationship to
Akt1 and NF-B activity
Recent evidence has indicated that the degenerate caspase
homologue cFLIP, whose expression is controlled by the
PI3K/Akt axis, can inhibit TRAIL-dependent apoptosis in pros-
tate tumor cells.32 Moreover, it seems that in some cell lines,
NF-B plays a key role in regulating expression of cFLIP,
which is inhibited by CHX.33 Since in AR cells procaspase-8
was not processed to active caspase 8, this suggested that
TRAIL resistance might arise from inhibition at the level of
caspase-8 activation. We therefore decided to analyze cFLIP
expression in HL60 cells. Western blotting analysis showed
that cFLIPL was less abundant in PT than in AR cells (Figure
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Figure 8 Immunofluorescent analysis for NF-B subcellular distri-
bution. HL60PT or AR cells, were fixed, permeabilized and immunos-
tained by an antibody to the p50 subunit of the NF-B transcription
factor, that was then revealed by a FITC-conjugated secondary anti-
body. DNA was revealed by DAPI counterstaining. For treatment with
Ly294002 cells were pre-incubated in the presence of the inhibitor
for 24 h. In the case of SN50, the inhibitor (30 g/ml) was present for
6 h. The pictures are representative of three separate experiments.
Scale bar: 5 M.
9a). If AR cells had been exposed to Ly294002, the cFLIPL
levels were similar to those of PT cells. The same was also
true of clone 4H1, overexpressing PTEN, whereas clone 12FC
(with a forced overexpression of constitutively active Akt1)
had cFLIPL levels comparable to AR cells. Finally, treatment
with either SN50 or CHX lowered the cFLIPL amount pro-
duced by AR cells. Although the antibody we employed
recognizes both the large and small forms of cFLIP, we never
detected the small form by Western blot. However, we
detected its mRNA by RT-PCR, but the amount was similar in
both PT and AR cells (not shown).
Evidence suggests that NF-B transcription factor may pro-
tect cells from TRAIL-induced apoptosis by up-regulating the
levels of the decoy receptor DcR1.34 We therefore sought to
determine whether or not there was a relationship between
TRAIL receptors expression and Akt1 and/or NF-B activity.
However, as presented in Figure 9a, it was evident that DcR1
was not expressed after treatment of HL60 AR cells with
Ly294002, SN50 or CHX, and in clones 4H1 or 12FC. More-
over, the levels of the three expressed receptors also did not
change under the same conditions.
Figure 9 cFLIPL expression, TRAIL-induced apoptosis and cas-
pase-8 activity correlate with NF-B activity. (A) Western blot analysis
for cFLIPL, DR4, DR5 and DcR2 in HL60 PT and AR cells and cell
clones 4H1 and 12FC. Equal protein loading was ensured by demon-
stration of uniform -tubulin expression. The blot is representative of
at least three separate experiments. (B) Flow cytometric analysis show-
ing the effect of SN50 or CHX on TRAIL-induced apoptosis in HL60AR
cells. Cells were incubated with TRAIL for 6 h after treatment with
either SN50 or CHX. (C) Demonstration of caspase-8 activity in
response to a 6 h incubation with 500 ng/ml TRAIL of HL60 PT and
AR cells and cell clones 4H1 and 12FC. In (b) and (c) the results
are the mean ± s.d. of three separate experiments. For treatment with
Ly294002 cells were pre-incubated in the presence of the inhibitor
for 24 h. In the case of SN50, the inhibitor (30 g/ml) was present for
6 h. In the experiments with CHX, the drug was present for 6 h at
0.1 g/ml.
cFLIPL levels correlate with apoptosis and caspase-8
activity
As presented in Figure 9b, there was a close relationship
between apoptosis and the amount of cFLIPL expressed by
HL60AR cells. Treatment with either SN50 or CHX markedly
increased the sensitivity of these cells to TRAIL. After exposure
to 200 ng/ml TRAIL, caspase-8 activity was higher in PT than
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AR cells, in which it could be raised by exposure to
Ly294002. Caspase-8 activity was also high in clone 4H1 and
in AR cells treated with either SN-50 or CHX (Figure 9c).
Discussion
In this paper, we have shown for the first time that Akt1 is a
crucial mediator of TRAIL resistance in HL60 leukemia cells.
Such a conclusion is based on several findings. In vivo phos-
phorylation and in vitro kinase activity were up-regulated in
a clone of HL60 cells, named AR cells. Both phosphorylation
and activity of Akt1 could be down-regulated by two unre-
lated pharmacological inhibitors of PI3K, Ly294002 and wort-
mannin. While HL60PT cells were highly sensitive to TRAIL
treatment, HL60AR cells displayed a strong resistance so that
a 6 h incubation in the presence of 2 g/ml TRAIL induced
apoptosis in only 14% of cells. The sensitivity to TRAIL of
HL60AR cells did not increase even if the incubation was pro-
longed to 24 h. However, pre-incubation of HL60AR cells
with Ly294002 or wortmannin concentrations that down-
regulated Akt1 phosphorylation and activity restored sensi-
tivity to TRAIL. To gain further evidence of the important role
played by Akt1 in conferring TRAIL resistance to HL60AR cells
we transfected these cells with PTEN. We selected three stably
transfected clones in which PTEN amount and activity was
higher than in AR cells. In these clones the amount of in vivo
synthesized PtdIns(3,4,5)P3 was lower than in AR cells. Also,
Akt1 phosphorylation and in vitro kinase activity were down-
regulated in the three clones. The three clones were sensitive
to a TRAIL concentration (500 ng/ml) to which AR cells were
resistant. Furthermore, we transfected PT cells with constitut-
ively active Akt1 cDNA and we selected three stably trans-
fected clones overexpressing Akt1. These clones had Akt1 kin-
ase activity significantly higher than PT cells and were
resistant up to 2 g/ml TRAIL. Therefore, the results gained
through a genetic approach also strongly supported the
hypothesis that up-regulation of Akt1 is of primary importance
for the TRAIL resistance observed in HL60AR cells.
We have ruled out the possibility that the TRAIL resistance
of HL60AR cells was due to a different expression of TRAIL
receptors when compared to PT cells. Indeed, Western blot-
ting analysis showed that DR4, DR5 and DcR2 receptors were
expressed to the same extent in the two types of cells. In
agreement with the findings of others27,28 we did not find
DcR1 in HL60 cells. Also, flow cytometric analysis demon-
strated that the receptor expression on the cell surface or in
the cytoplasm did not vary between PT and AR cells.
TRAIL activated procaspase-8 but not procaspase-10 or -9
in HL60PT cells. This finding is consistent with the report of
others,11 who showed procaspase-8 to be the apical caspase
of TRAIL-induced apoptosis in hematopoietic malig-
nancies.11,35,36 In contrast, recruitment of procaspase-10 to the
TRAIL receptors DR4 and DR5 has been demonstrated in
some solid tumors.37,38 We did not detect cleavage of procas-
pase-8 in AR cells. However, if these cells had been exposed
to PI3K inhibitors, procaspase-8 cleavage became evident.
Also, the use of selective caspase inhibitors strongly suggested
an involvement of caspase-8 but not of caspase-9 in TRAIL-
mediated apoptotic death of HL60 cells, since Z-IETD-FMK,
an inhibitor of caspase-8, blocked apoptosis of HL60PT cells,
whereas Z-LEHD-FMK, an inhibitor of caspase-9, was ineffec-
tive. Consistent with these findings, AR cells, pre-treated with
either Ly294002 or wortmannin, did not undergo apoptosis in
the presence of TRAIL plus Z-IETD-FMK, while they did if Z-
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LEHD-FMK was employed together with TRAIL. Similar results
were recently reported for K562 cells.39
However, we detected TRAIL-evoked BID cleavage in PT
cells or in AR cells exposed to PI3K inhibitors. Interestingly,
in agreement with the findings of others, we did not detect
the cleavage products of BID,28 even though the antibody we
employed does. Moreover, we did not see release of cyto-
chrome c from mitochondria in PT cells treated with TRAIL.
Once released from mitochondria, cytochrome c in complex
with apoptotic protease-activating factor 1 (Apaf-1) activates
caspase-9, which in turn activates the executioner casp-
ases.40,41 In some types of cells, referred to as type II cells,
caspase-8 activation leads, through the cleavage of BID, to
the release of cytochrome c from mitochondria. On the other
hand, cells of hematopoietic lineage, are considered to be
type I cells, that is cells in which TRAIL does not activate the
mitochondrial pathway of apoptosis.11 Taken together, our
results strongly suggest that the mitochondrial pathway, even
though BID is cleaved, is not activated by TRAIL in HL60
cells. We are presently investigating why, despite the BID
cleavage, there is no cytochrome c release from mitochondria.
Our findings suggest that neither Bcl-XL nor Bcl-2 is capable
of blocking TRAIL-induced apoptosis in the HL60 cells we
employed. These findings are not consistent with data from
others who showed that both of these proteins, when
ectopically overexpressed, could block TRAIL-dependent
apoptosis of HL60 cells by inhibiting activation of procaspase-
8.28 It should be emphasized, however, that the mechanism
through which Bcl-2 and/or Bcl-XL would inhibit receptor-
mediated apoptosis is not clear. Both Bcl-2 and Bcl-XL reside
on the outer mitochondrial membrane, whereas caspase-8 is
on the plasma membrane as a component of the TRAIL–recep-
tor complex. At present, we have no explanation for the dis-
crepancy between our findings and the results of others,28
although we could hypothesize that Bcl-2 and/or Bcl-XL are
capable of blocking TRAIL-evoked apoptosis only if they are
overexpressed and produced in an amount which is not
physiological. Indeed, it might be that these proteins, when
overexpressed, exist as soluble forms capable of blocking the
activation of membrane-bound procaspase-8.
We have explored the possibility that Akt1 up-regulation
observed in HL-60 AR cells exerts its antiapoptotic effect
through the transcription factor NF-B. Indeed, Akt phos-
phorylates and activates IKK-, which in turns phosphorylates
I-B, thus promoting the nuclear translocation of NF-B. NF-
B controls the transcription of genes fundamental for sur-
vival, such as cFLIP, cIAP1, cIAP2, TRAF-1 and TRAF-2.17 The
results of immunofluorescence analysis showed that the p50
subunit of NF-B was localized in the cytoplasm of HL60PT
cells, whereas in AR cells it was present in the nucleus. If AR
cells were treated with Ly294002 the p50 subunit was located
in the cytoplasm. This intracellular distribution of the p50 sub-
unit was also seen when AR cells were treated with SN50, a
synthetic peptide containing a cell membrane-permeable
motif and nuclear localization sequence of the p50 subunit.
SN50 inhibits nuclear translocation and transcriptional
activity of NF-B.41 Moreover, p50 subunit was cytoplasmic
in clone 4H1 whereas it was intranuclear in clone 12FC.
HL60AR expressed levels of the caspase degenerate homol-
ogue cFLIPL higher than PT cells. cFLIPL expression was sensi-
tive to treatment of AR cells with Ly294002, wortmannin,
SN50 and CHX. Moreover, the amount of cFLIPL was lower
in clone 4H1 and higher in clone 12FC. These findings sug-
gest that in HL60 cells the expression of cFLIPL is regulated
by Akt1 through a NF-B-dependent mechanism. There was
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a close relationship between the levels of cFLIPL expressed by
HL60 cells and the activity of caspase-8. High levels of cFLIPL
were coupled with a low caspase-8 activity and vice versa.
Importantly, treatment with SN50 or CHX sensitized HL60AR
cells to the proapoptotic action of TRAIL.
cFLIP is rapidly emerging as a key molecule which can
block death receptor-mediated apoptosis. Indeed, this protein
is capable of binding to the adapter protein FADD (Fas-asso-
ciated death domain) which is a key component of the death-
inducing signaling complex. However, cFLIP cannot be
cleaved to an active caspase thus preventing the initiation of
the death pathway. In some types of solid tumors it has been
found that Akt regulates the expression of cFLIP.32 There are
several alternative spliced transcripts of cFLIP in mammalian
cells, but only two can be detected at the protein level: the
short form (cFLIPS) and the long form (cFLIPL).42 Very recently,
a higher constitutive expression of cFLIPL in B chronic lym-
phocytic leukemia cells was observed as compared to normal
tonsillar B cells.43 It is of great interest that B-chronic lympho-
cytic leukemia cells were relatively resistant to TRAIL-induced
apoptosis. It should be recalled that in other cell types, such
as HeLa cells, cFLIPS appears to be a major cellular inhibitor
of TRAIL-induced apoptosis.44
Our findings also ruled out that NF-B activation could lead
to changes in the expression levels of TRAIL receptors. Indeed,
there is a study in which an up-regulation of DcR1 was shown
to be dependent on NF-B activity and could make HeLa cells
resistant to TRAIL.34
Overall, the data presented here indicate that in HL60AR
cells TRAIL resistance is mediated by an activation of the
Akt1/NF-B pathway. So far, Akt1 has been linked to TRAIL
resistance only in prostatic cancer cells,12,20,21,45 but our
results indicate that this serine/threonine protein kinase may
also affect TRAIL sensitivity in neoplastic cells of hematopo-
ietic lineage. Akt can be regarded as a powerful antiapoptotic
oncoprotein and, as such, it is one of the most attractive kin-
ase targets in cancer cells for the development of new pharma-
cological tools to sensitize cells to treatments inducing
apoptosis. TRAIL may be a novel therapeutic agent for human
neoplastic diseases, including those of hematopoietic origin.27
In light of our findings, treatment with agents that down-regu-
late Akt activity should be useful in cases of TRAIL resistance
due to an up-regulation of the PI3K/Akt pathway. Moreover,
our data confirm the usefulness of pharmacological agents
that down-regulate NF-B activity to overcome resistance to
TRAIL.11,27,46
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